Literature DB >> 21450480

Orthotopic heart transplantation with donors greater than or equal to 60 years of age: a single-center experience.

Giuseppe Bruschi1, Tiziano Colombo, Fabrizio Oliva, Nuccia Morici, Luca Botta, Aldo Cannata, Maria Frigerio, Luigi Martinelli.   

Abstract

OBJECTIVES: Heart transplantation is the best therapeutic option for patients suffering from end-stage heart failure, but donor organ availability still represents a major problem. This had led to a shift toward extended donor criteria. The aim of the present study is to analyze the short- and long-term results of heart transplantation in patients with donor age ≥ 60 years.
METHODS: Since November 1985, 890 patients have been transplanted at our center. We consider, for the present study, only primary adult heart transplantations performed after 1990, totaling 761 patients, mean age at transplantation 49.8 years, and 616 patients being male (81%). We compare the short- and long-term results of patients transplanted with donors younger than 60 years or ≥ 60 years.
RESULTS: Since 1990, at our center, 711 patients have been heart transplanted with a donor younger than 60 years, while 50 patients received a heart from a donor older than 60 years. No differences have been reported in the etiology of cardiomyopathy, previous surgery, or mean ischemic time. Patients transplanted with donors ≥ 60 years of age were significantly older compared to the younger donors' group. Donor cause of death was a cerebrovascular accident in 82% of donors ≥ 60 years versus 41% in younger donors. Patients' heart transplanted with donors ≥ 60 years had a higher incidence of acute graft failure with a hospital mortality of 32% (16 patients) significantly higher compared with 10.2% for the other group. No differences were noticed in the incidence of renal failure, acute rejection treated, coronary allograft vasculopathy, and neoplasm during long-term follow-up.
CONCLUSIONS: It was possible to expand the cardiac donor pool by accepting allografts from donors ≥ 60 years of age in selected cases by performing a coronary angiogram. A meticulous donor evaluation and a careful risk assessment between the risk of death on the waiting list and probable increased hospital mortality are needed.
Copyright © 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21450480     DOI: 10.1016/j.ejcts.2011.02.013

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Mid-term survival after continuous-flow left ventricular assist device versus heart transplantation.

Authors:  Enrico Ammirati; Fabrizio G Oliva; Tiziano Colombo; Claudio F Russo; Manlio G Cipriani; Andrea Garascia; Valentina Guida; Giulia Colombo; Alessandro Verde; Enrico Perna; Aldo Cannata; Roberto Paino; Luigi Martinelli; Maria Frigerio
Journal:  Heart Vessels       Date:  2015-03-04       Impact factor: 2.037

Review 2.  Heart Transplant Donor Selection Guidelines: Review and Recommendations.

Authors:  Shyama Sathianathan; Geetha Bhat
Journal:  Curr Cardiol Rep       Date:  2022-02-18       Impact factor: 2.931

3.  Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7.

Authors:  Andrea Vergani; Sara Tezza; Francesca D'Addio; Carmen Fotino; Kaifeng Liu; Monika Niewczas; Roberto Bassi; R Damaris Molano; Sonja Kleffel; Alessandra Petrelli; Antonio Soleti; Enrico Ammirati; Maria Frigerio; Gary Visner; Fabio Grassi; Maria E Ferrero; Domenico Corradi; Reza Abdi; Camillo Ricordi; Mohamed H Sayegh; Antonello Pileggi; Paolo Fiorina
Journal:  Circulation       Date:  2012-12-18       Impact factor: 29.690

4.  Successful heart transplantation from a donor with Ullrich congenital muscular dystrophy.

Authors:  C Plonka; P D Wearden; V O Morell; S A Miller; S A Webber; B Feingold
Journal:  Am J Transplant       Date:  2013-05-13       Impact factor: 8.086

5.  Trends in the utilization of marginal donors for orthotopic heart transplantation.

Authors:  Lauren V Huckaby; Gavin Hickey; Ibrahim Sultan; Arman Kilic
Journal:  J Card Surg       Date:  2021-01-23       Impact factor: 1.778

6.  miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.

Authors:  Vera Usuelli; Moufida Ben Nasr; Francesca D'Addio; Kaifeng Liu; Andrea Vergani; Basset El Essawy; Jun Yang; Emma Assi; Mayuko Uehara; Chiara Rossi; Anna Solini; Annalisa Capobianco; Elena Rigamonti; Luciano Potena; Massimo Venturini; Mario Sabatino; Lorena Bottarelli; Enrico Ammirati; Maria Frigerio; Eduardo Castillo-Leon; Anna Maestroni; Cinzia Azzoni; Cristian Loretelli; Andy Joe Seelam; Albert K Tai; Ida Pastore; Gabriella Becchi; Domenico Corradi; Gary A Visner; Gian V Zuccotti; Nelson B Chau; Reza Abdi; Marcus G Pezzolesi; Paolo Fiorina
Journal:  Am J Transplant       Date:  2021-05-03       Impact factor: 9.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.